Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Clinical trial NCT00790010 · COMPLETED
Trial details
- NCT number
- NCT00790010
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-02-26
- Primary completion
- 2018-06-22
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.